All In Biotech

Drug Trial Radar · NCT05225857

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Feb 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jun 28, 2022

Primary completion

Jan 13, 2024

Study completion Jan 13, 2024

Sponsor

Lead sponsor
Angitia BiopharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Angitia Australia Pty Ltd
First posted
Feb 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations in men and postmenopausal women.

Conditions

  • Osteoporosis

Interventions

  • AGA2118Drug

    Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.

  • PlaceboDrug

    Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAE) in Part 1 (SAD).Time frame: Up to 85 days
  2. Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 1 (SAD).Time frame: Up to 85 days
  3. Number of participants with clinically significant changes in blood pressure in Part 1 (SAD).Time frame: Up to 85 days
  4. Number of participants with clinically significant changes in heart rate in Part 1 (SAD).Time frame: Up to 85 days
  5. Number of participants with clinically significant changes in QTcF in Part 1 (SAD).Time frame: Up to 85 days
  6. Number of participants with treatment-emergent adverse events (TEAE) in Part 2 (MAD).Time frame: Up to 169 days
  7. Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 2 (MAD).Time frame: Up to 169 days
  8. Number of participants with clinically significant changes in blood pressure in Part 2 (MAD).Time frame: Up to 169 days
  9. Number of participants with clinically significant changes in heart rate in Part 2 (MAD).Time frame: Up to day 169
  10. Number of participants with clinically significant changes in QTcF in Part 2 (MAD).Time frame: Up to day 169

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd

    Brisbane, Queensland, Australia

  • Nucleus Network Pty Ltd.

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.